Clinical Trial Update: Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial examining transdermal flumazenil to modulate GABA-A receptors in Parkinson disease; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Flumazenil (transdermal) (flumazenil)

Snippet

Sponsor: Nicolaas Bohnen, MD, PhD | Conditions: Parkinson Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-01-10